Develop and commercialize medications for hospital settings. Focus on therapeutic areas including sedation, anesthesia, and critical care management. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 86% a year over the last 4 years. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 4 years, sales grew about 86% a year on average.
Sales run at $37.2M a year. A small number, but proof the product has real buyers.
A loss of $648K against $37.2M in annual sales.
The stock sits at $0.07. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
This stock swings about 4.1 times as much as the market average. Big rallies — and big drops — can both happen fast.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.